Etrumadenant + IPI-549 + Pegylated liposomal doxorubicin (PLD) + nanoparticle albumin-bound paclitaxel (NP)
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
TNBC - Triple-Negative Breast Cancer
Conditions
TNBC - Triple-Negative Breast Cancer, Ovarian Cancer
Trial Timeline
Oct 15, 2018 → Jul 2, 2021
NCT ID
NCT03719326About Etrumadenant + IPI-549 + Pegylated liposomal doxorubicin (PLD) + nanoparticle albumin-bound paclitaxel (NP)
Etrumadenant + IPI-549 + Pegylated liposomal doxorubicin (PLD) + nanoparticle albumin-bound paclitaxel (NP) is a phase 1 stage product being developed by Arcus Biosciences for TNBC - Triple-Negative Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03719326. Target conditions include TNBC - Triple-Negative Breast Cancer, Ovarian Cancer.
What happened to similar drugs?
0 of 2 similar drugs in TNBC - Triple-Negative Breast Cancer were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
6
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03719326 | Phase 1 | Completed |
Competing Products
14 competing products in TNBC - Triple-Negative Breast Cancer